Latest News for CZMWF
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China's intraocular lens business.
Carl Zeiss Meditec AG is rated a "Buy" despite recent operational weakness and geopolitical headwinds, especially in Asia-Pacific and North America. Sales declined 4.8% in Q1, with margin compression and a suspended 2025/2026 outlook due to weak demand across Asia-Pacific and North America. CZMWF now trades at a significant discount to peers, with a 2026 price target of $39.26, implying ~20% upside against a…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CZMWF.
Senate Trading
No Senate trades found for CZMWF.
U.S. House Trading
No House trades found for CZMWF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.